Target intelligence / Profile preview

Volume-regulated anion channel subunit LRRC8D (LRRC8D)

Target
LRRC8D
Molecular classification
Ion channel, Volume-regulated anion channel (VRAC) subunit, Transmembrane protein
01

Overview

Volume-regulated anion channel subunit LRRC8D (LRRC8D) is a pore-forming component of the volume-regulated anion channel (VRAC), which controls cell volume by mediating the flux of chloride ions and diverse organic osmolytes in response to cell swelling[1][2][3][4]. LRRC8D must heteromerize with LRRC8A and other LRRC8 subunits (LRRC8B–E) to form functional VRACs, with the exact subunit composition conferring permeability to a broad spectrum of organic substrates—including amino acids and drugs like cisplatin[1][4]. Structural studies show LRRC8D-containing channels have a wider extracellular pore constriction compared to LRRC8A, suggesting a basis for their more permissive substrate selectivity[1][2][3]. LRRC8D is essential for the cellular entry of certain chemotherapeutics and antibiotics, making its expression a key factor in drug sensitivity, especially in tumors where downregulation of LRRC8D leads to chemoresistance[1].

Other names
Leucine-rich repeat-containing 8 VRAC subunit DLeucine-rich repeat-containing protein 8DLeucine-rich repeat-containing protein 5LRRC5HsLRRC8DFLJ10470UNQ213/PRO239Leucine rich repeat containing 8 family member D
02

Mechanism of action

Drug entry through VRAC when LRRC8D is present in heteromers (increases uptake of certain chemotherapeutic and antibiotic agents; loss reduces cellular uptake and leads to resistance)

03

Biological functions

Regulation of cell volume (cell volume homeostasis)Osmolyte and ion transportOrganic osmolyte permeability (taurine, GABA, glutamate, lysine, etc.)Facilitates uptake of certain drugs (e.g., cisplatin, blasticidin S)
04

Disease associations

Cancer (particularly in drug resistance to platinum-based chemotherapy like cisplatin)Other (modulation of cell swelling could be relevant to additional pathologies, but cancer drug resistance is most clearly documented)
05

Safety considerations

Potential for acquired drug resistance in cancer therapy due to decreased LRRC8D expressionPossible off-target effects due to disruption of general cell volume regulation if targeted therapeutically
06

Interacting drugs

Cisplatin

1 more in the full profile.

07

Biomarkers

LRRC8D expression (downregulation can serve as a biomarker for acquired resistance to platinum-based cancer drugs)

Beyond the preview

Go deeper on Volume-regulated anion channel subunit LRRC8D (LRRC8D).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Volume-regulated anion channel subunit LRRC8D (LRRC8D).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call